Aytu BioPharma Q4 2024 GAAP EPS $(0.82) Misses $(0.45) Estimate, Sales $18.00M Miss $18.30M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aytu BioPharma reported a Q4 2024 GAAP EPS of $(0.82), missing the $(0.45) estimate, and sales of $18.00M, missing the $18.30M estimate. This represents a 41.43% decrease in sales compared to the same period last year.
September 26, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aytu BioPharma's Q4 2024 earnings report showed a significant miss on both EPS and sales estimates, with a notable year-over-year sales decline.
The significant miss on EPS and sales estimates, along with a large year-over-year sales decline, suggests negative investor sentiment and potential short-term stock price pressure.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100